This guidelines are aimed to assist industry (marketing authorization holders) in drawing up the label and package leaflet for their products in compliance with the Drugs (Labelling and Packing) Rules 1986. This documents will provide specific requirements for the labelling and packaging of pharmaceutical and biological drug products.
The purpose of the guidelines are:-
- To provide guidance on how to ensure that the information on the label and package leaflet is accessible to and can be understood by those who receive it, so that they can use their medicine or ensure its use safely and appropriately.
- To help achieve consistency, transparency, clarity, efficiency and high quality in both the content and management of reviews.
- This guideline is written to assist applicants and marketing authorization holders when drawing up the label and package leaflet
Stakeholders can submit their comments and suggestions with 15 days of uploading of this document using prescribed format to submit comments (link to access table of comments), and forward via email to email@example.com, copying at firstname.lastname@example.org, or can post at mailing address Additional Director, Pharmaceutical Evaluation and Registration, 4th floor TF Complex, 7th Mauve Area, G-9/4, Islamabad.
Please click here to view draft guidance document Draft Guidelines on Labelling and Packaging of Drug Products